CytomX Therapeutics Inc (NASDAQ: CTMX) on Monday, soared 3.60% from the previous trading day, before settling in for the closing price of $1.11. Within the past 52 weeks, CTMX’s price has moved between $0.83 and $5.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 28.25% annually for the last half of the decade. The company achieved an average annual earnings per share of -328.04%. With a float of $76.94 million, this company’s outstanding shares have now reached $78.23 million.
In an organization with 122 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 98.88%, operating margin of 5.3%, and the pretax margin is 11.89%.
CytomX Therapeutics Inc (CTMX) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of CytomX Therapeutics Inc is 1.69%, while institutional ownership is 65.49%. The most recent insider transaction that took place on Aug 20 ’24, was worth 5,139. In this transaction Chief Business Officer of this company sold 4,181 shares at a rate of $1.23, taking the stock ownership to the 119,056 shares. Before that another transaction happened on Aug 20 ’24, when Company’s SVP, Chief Scientific Officer sold 4,181 for $1.23, making the entire transaction worth $5,139. This insider now owns 175,648 shares in total.
CytomX Therapeutics Inc (CTMX) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.02 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -328.04% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -0.90% during the next five years compared to 67.21% growth over the previous five years of trading.
CytomX Therapeutics Inc (NASDAQ: CTMX) Trading Performance Indicators
CytomX Therapeutics Inc (CTMX) is currently performing well based on its current performance indicators. A quick ratio of 1.04 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 0.70.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 0.17, a number that is poised to hit -0.20 in the next quarter and is forecasted to reach -0.43 in one year’s time.
Technical Analysis of CytomX Therapeutics Inc (CTMX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.85 million. That was inferior than the volume of 2.46 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 22.11%. Additionally, its Average True Range was 0.10.
During the past 100 days, CytomX Therapeutics Inc’s (CTMX) raw stochastic average was set at 46.82%, which indicates a significant increase from 44.90% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 87.24% in the past 14 days, which was higher than the 61.93% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $1.0694, while its 200-day Moving Average is $1.5414. However, in the short run, CytomX Therapeutics Inc’s stock first resistance to watch stands at $1.1783. Second resistance stands at $1.2067. The third major resistance level sits at $1.2533. If the price goes on to break the first support level at $1.1033, it is likely to go to the next support level at $1.0567. Assuming the price breaks the second support level, the third support level stands at $1.0283.
CytomX Therapeutics Inc (NASDAQ: CTMX) Key Stats
Market capitalization of the company is 89.20 million based on 78,259K outstanding shares. Right now, sales total 101,210 K and income totals -570 K. The company made 33,430 K in profit during its latest quarter, and 5,740 K in sales during its previous quarter.
